Pulmonary Fibrosis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 380 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pulmonary Fibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Pulmonary Fibrosis - Pipeline Review, H1 2016', provides an overview of the Pulmonary Fibrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content
Table of Contents 2

List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Pulmonary Fibrosis Overview 11
Therapeutics Development 12
Pipeline Products for Pulmonary Fibrosis - Overview 12
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 13
Pulmonary Fibrosis - Therapeutics under Development by Companies 14
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 20
Pulmonary Fibrosis - Pipeline Products Glance 21
Clinical Stage Products 21
Early Stage Products 22
Pulmonary Fibrosis - Products under Development by Companies 23
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 30
Pulmonary Fibrosis - Companies Involved in Therapeutics Development 31
AdAlta Pty Ltd. 31
Advinus Therapeutics Ltd. 32
Aeolus Pharmaceuticals, Inc. 33
Afferent Pharmaceuticals, Inc. 34
AnaMar AB 35
Angion Biomedica Corp. 36
Antitope Limited 37
aTyr Pharma, Inc. 38
Biogen, Inc. 39
Bioneer Corporation 40
BiOrion Technologies B.V. 41
Bristol-Myers Squibb Company 42
Carolus Therapeutics, Inc. 43
Celgene Corporation 44
Chong Kun Dang Pharmaceutical Corp. 45
Clanotech AB 46
Compugen Ltd. 47
Cynata Therapeutics Limited 48
Diffusion Pharmaceuticals Inc. 49
Digna Biotech, S.L. 50
Elsalys Biotech SAS 51
F. Hoffmann-La Roche Ltd. 52
FibroGen, Inc. 53
Galapagos NV 54
Galectin Therapeutics, Inc. 55
GenKyoTex S.A. 56
GlaxoSmithKline Plc 57
Global Blood Therapeutics, Inc. 58
HanAll Biopharma Co., Ltd. 59
HEC Pharm Co., Ltd. 60
Histocell S.L. 61
Hydra Biosciences, Inc. 62
iBio, Inc. 63
Inventiva 64
Isarna Therapeutics GmbH 65
Kadmon Corporation, LLC 66
Kasiak Research Private Limited 67
KineMed, Inc. 68
Kyorin Pharmaceutical Co., Ltd. 69
Lpath, Inc. 70
miRagen Therapeutics, Inc. 71
Moerae Matrix, Inc. 72
MorphoSys AG 73
NicOx S.A. 74
Novartis AG 75
Pacific Therapeutics Ltd. 76
Pharmaxis Limited 77
Pharmicell Co., Ltd. 78
Pluristem Therapeutics Inc. 79
Progenra, Inc. 80
Promedior, Inc. 81
ProMetic Life Sciences Inc. 82
Pulmatrix, Inc. 83
RedHill Biopharma Ltd. 84
Respira Therapeutics, Inc. 85
Rhizen Pharmaceuticals S.A. 86
Ribomic Inc. 87
Saje Pharma, LLC 88
Sanofi 89
SciFluor Life Sciences, LLC 90
Symic Biomedical, Inc. 91
TaiwanJ Pharmaceuticals Co., Ltd. 92
Teva Pharmaceutical Industries Limited 93
Therabron Therapeutics, Inc. 94
Vericel Corporation 95
Yuhan Corporation 96
Pulmonary Fibrosis - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Target 99
Assessment by Mechanism of Action 103
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 111
(acetylcysteine + pentoxifylline) - Drug Profile 111
ABC-294640 - Drug Profile 113
acALY-18 - Drug Profile 116
AEOL-10150 - Drug Profile 117
AF-219 - Drug Profile 121
Altepan - Drug Profile 123
AM-0010 - Drug Profile 124
AMAP-102 - Drug Profile 126
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 128
Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile 129
BB-3 - Drug Profile 130
BG-00011 - Drug Profile 134
BMS-986020 - Drug Profile 135
BOT-191 - Drug Profile 136
CC-539 - Drug Profile 137
CC-90001 - Drug Profile 138
Cellgram-Lung - Drug Profile 139
CG-1011 - Drug Profile 140
CGEN-25009 - Drug Profile 141
CKD-942 - Drug Profile 142
CLT-28643 - Drug Profile 143
CM-101 - Drug Profile 144
CMYJH-01 - Drug Profile 145
CT-140 - Drug Profile 146
CT-2009 - Drug Profile 147
D-9030 - Drug Profile 148
DB-02901 - Drug Profile 149
disitertide - Drug Profile 150
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 153
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 154
FG-3019 - Drug Profile 155
GBT-1118 - Drug Profile 157
GBT-440 - Drug Profile 158
GKT-831 - Drug Profile 159
GLPG-1690 - Drug Profile 160
GRMD-02 - Drug Profile 161
GSK-3008348 - Drug Profile 164
HC-067047 - Drug Profile 165
HEC-00000585 - Drug Profile 166
HL-156FIB - Drug Profile 167
HR-017 - Drug Profile 168
IBIOCFB-03 - Drug Profile 169
ICG-001 - Drug Profile 171
iMod.Fc - Drug Profile 172
ISTH-0047 - Drug Profile 173
ITMN-10534 - Drug Profile 175
ITMN-14440 - Drug Profile 176
ITMN-30162 - Drug Profile 177
IVA-337 - Drug Profile 178
ixmyelocel-T - Drug Profile 179
JKB-117 - Drug Profile 182
JKB-119 - Drug Profile 183
KBP-7018 - Drug Profile 184
KD-025 - Drug Profile 185
lebrikizumab - Drug Profile 187
Lpathomab - Drug Profile 189
LT-0011 - Drug Profile 191
LTI-03 - Drug Profile 192
MGN-4220 - Drug Profile 193
MMI-0100 - Drug Profile 194
Monoclonal Antibodies to Inhibit S100-B for Idiopathic Pulmonary Fibrosis and COPD - Drug Profile 196
MOR-107 - Drug Profile 197
NAS-911 - Drug Profile 198
NCX-466 - Drug Profile 200
Neumomir - Drug Profile 201
noscapine - Drug Profile 202
Oligonucleotides for Respiratory and Oncology - Drug Profile 203
OLX-201 - Drug Profile 204
omipalisib - Drug Profile 205
P-007 - Drug Profile 207
P-013 - Drug Profile 208
PB-01 - Drug Profile 209
PBF-1129 - Drug Profile 211
PBI-4050 - Drug Profile 212
PBI-4425 - Drug Profile 214
Peptide to Target C/EBP-Beta for Lung Fibrosis - Drug Profile 215
pirfenidone - Drug Profile 216
PLX-PAD - Drug Profile 217
PNQ-103 - Drug Profile 221
PRI-724 - Drug Profile 222
PRM-151 - Drug Profile 224
PUR-1500 - Drug Profile 226
PXS-4820 - Drug Profile 227
Q-122 - Drug Profile 228
RBM-005 - Drug Profile 230
RBM-006 - Drug Profile 231
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 232
Recombinant Peptides for Fibrosis - Drug Profile 233
Recombinant Protein for Inflammation and Pulmonary Fibrosis - Drug Profile 234
Refacell-IPF - Drug Profile 235
RES-529 - Drug Profile 236
RP-3128 - Drug Profile 239
RP-6503 - Drug Profile 240
RT-234 - Drug Profile 241
SAR-156597 - Drug Profile 242
SB-300 - Drug Profile 243
SD-560 - Drug Profile 244
SM-04646 - Drug Profile 245
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile 246
Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 247
Small Molecule to Inhibit MAPK for Pulmonary Fibrosis - Drug Profile 248
Small Molecules for COPD and IPF - Drug Profile 249
Small Molecules for Fibrosis - Drug Profile 250
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 251
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 252
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 253
Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile 254
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 255
Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile 256
Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis - Drug Profile 257
Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile 258
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 259
SPL-334 - Drug Profile 260
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 261
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile 262
Stem Cell Therapy for Lung Fibrosis - Drug Profile 263
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 264
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 266
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 268
TD-139 - Drug Profile 269
tipelukast - Drug Profile 271
TM-5441 - Drug Profile 273
vismodegib - Drug Profile 275
YH-siRNA1 - Drug Profile 279
ZL-2102 - Drug Profile 280
Pulmonary Fibrosis - Recent Pipeline Updates 281
Pulmonary Fibrosis - Dormant Projects 356
Pulmonary Fibrosis - Discontinued Products 362
Pulmonary Fibrosis - Product Development Milestones 363
Featured News & Press Releases 363
Appendix 370
Methodology 370
Coverage 370
Secondary Research 370
Primary Research 370
Expert Panel Validation 370
Contact Us 370
Disclaimer 371

List of Tables

Number of Products under Development for Pulmonary Fibrosis, H1 2016 21
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 23
Number of Products under Development by Companies, H1 2016 (Contd..1) 24
Number of Products under Development by Companies, H1 2016 (Contd..2) 25
Number of Products under Development by Companies, H1 2016 (Contd..3) 26
Number of Products under Development by Companies, H1 2016 (Contd..4) 27
Number of Products under Development by Companies, H1 2016 (Contd..5) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Development, H1 2016 31
Products under Development by Companies, H1 2016 32
Products under Development by Companies, H1 2016 (Contd..1) 33
Products under Development by Companies, H1 2016 (Contd..2) 34
Products under Development by Companies, H1 2016 (Contd..3) 35
Products under Development by Companies, H1 2016 (Contd..4) 36
Products under Development by Companies, H1 2016 (Contd..5) 37
Products under Development by Companies, H1 2016 (Contd..6) 38
Products under Investigation by Universities/Institutes, H1 2016 39
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2016 40
Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2016 41
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 42
Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 43
Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2016 44
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016 45
Pulmonary Fibrosis - Pipeline by Antitope Limited, H1 2016 46
Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H1 2016 47
Pulmonary Fibrosis - Pipeline by Biogen, Inc., H1 2016 48
Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H1 2016 49
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016 50
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 51
Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016 52
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2016 53
Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 54
Pulmonary Fibrosis - Pipeline by Clanotech AB, H1 2016 55
Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2016 56
Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H1 2016 57
Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 58
Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2016 59
Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H1 2016 60
Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 61
Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2016 62
Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2016 63
Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 64
Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2016 65
Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016 66
Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H1 2016 67
Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 68
Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016 69
Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2016 70
Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H1 2016 71
Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2016 72
Pulmonary Fibrosis - Pipeline by Inventiva, H1 2016 73
Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016 74
Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H1 2016 75
Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H1 2016 76
Pulmonary Fibrosis - Pipeline by KineMed, Inc., H1 2016 77
Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 78
Pulmonary Fibrosis - Pipeline by Lpath, Inc., H1 2016 79
Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2016 80
Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2016 81
Pulmonary Fibrosis - Pipeline by MorphoSys AG, H1 2016 82
Pulmonary Fibrosis - Pipeline by NicOx S.A., H1 2016 83
Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2016 84
Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2016 85
Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2016 86
Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H1 2016 87
Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H1 2016 88
Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2016 89
Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2016 90
Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016 91
Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2016 92
Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H1 2016 93
Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H1 2016 94
Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 95
Pulmonary Fibrosis - Pipeline by Ribomic Inc., H1 2016 96
Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H1 2016 97
Pulmonary Fibrosis - Pipeline by Sanofi, H1 2016 98
Pulmonary Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016 99
Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H1 2016 100
Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 101
Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 102
Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H1 2016 103
Pulmonary Fibrosis - Pipeline by Vericel Corporation, H1 2016 104
Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H1 2016 105
Assessment by Monotherapy Products, H1 2016 106
Assessment by Combination Products, H1 2016 107
Number of Products by Stage and Target, H1 2016 109
Number of Products by Stage and Mechanism of Action, H1 2016 113
Number of Products by Stage and Route of Administration, H1 2016 117
Number of Products by Stage and Molecule Type, H1 2016 119
Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016 290
Pulmonary Fibrosis - Dormant Projects, H1 2016 365
Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2016 366
Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2016 367
Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2016 368
Pulmonary Fibrosis - Dormant Projects (Contd..4), H1 2016 369
Pulmonary Fibrosis - Dormant Projects (Contd..5), H1 2016 370
Pulmonary Fibrosis - Discontinued Products, H1 2016 371